Good Manufacturing Practices (GMP): Manufacturing Control, Sanitation, and Quality Systems

Vocabulary flashcards reviewing core Good Manufacturing Practices (GMP) concepts under Health Canada Food and Drug Regulations (Part C, Division 2), covering equipment, sanitation, raw material testing, manufacturing control, recalls, self-inspection, and quality control responsibilities.

Section C.02.005

A regulation under Division 2 of the Food and Drug Regulations governing equipment, requiring it to be designed, constructed, located, and maintained to permit cleaning, sanitizing, and inspection, and operated to prevent cross-contamination.

Section C.02.007

A GMP regulation requiring fabricators and packagers/labellers to have a written sanitation program based on quality risk management to maintain cleanliness and prevent contamination of premises and equipment.

Section C.02.008

A GMP regulation requiring written minimum requirements for health, hygienic behaviour, and clothing of personnel, and barring individuals with communicable diseases or open lesions from areas where drugs are exposed.

Raw Material (Drug Product)

Active pharmaceutical ingredients (APIs), excipients, and packaging materials that serve as the base components to develop or produce a finished drug product.

Excipient

An inactive substance formulated alongside the active ingredient that serves functional roles such as filler, binder, disintegrant, glidant, lubricant, preservative, or stabilizer.

Binder

An excipient, such as polyvinylpyrrolidone (PVP), hydroxypropyl cellulose (HPC), starch, or gelatin, that binds powder ingredients together to form granules for processing into solid dosage forms.

Polyvinylpyrrolidone (PVP) Structure

The chemical structure of polyvinylpyrrolidone (PVP), a common tablet binder typically used in aqueous, alcoholic, or hydroalcoholic solutions at concentrations of $5\%$ to $20\%\,w/v$.

Section C.02.009

A GMP regulation mandating that each lot or batch of raw material be tested against approved specifications prior to its use in the fabrication of a drug, with an exception allowing water to be used prior to test completion.

Specification

A formal quality standard establishing a list of tests, references to analytical procedures, and appropriate acceptance criteria to which a raw material, packaging material, or finished product must conform.

Water for Injection (WFI)

High-purity water required to formulate parenteral, irrigation, and intra-ocular products, which must be sampled daily from at least two rotating outlets and tested for microbial load and bacterial endotoxins.

Composite Sample (Raw Material)

A single sample formed by combining portions from individual containers (up to a maximum of 10 containers) of a raw material lot, permitted only when a specifically discriminating test and a potency test are performed.

Section C.02.010

A GMP regulation detailing raw material testing options, allowing testing before receipt for certified vendors with periodic confirmatory testing, but strictly requiring specific identity testing on every lot after receipt on the fabricator premises.

Vendor Certification

A formal qualification process involving written agreements, audit reports, full confirmatory testing on the first 3 lots and at least one lot annually, allowing a fabricator to rely on supplier certificates of analysis.

Manufacturing Control

The systematic planning, coordinating, and directing of all manufacturing activities and influences to ensure products are produced on time, within budget, and with the required quality, safety, and effectiveness.

Section C.02.011

A GMP regulation requiring fabricators, packagers/labellers, distributors, and importers to maintain written procedures prepared by qualified personnel to ensure drugs meet specifications, and to verify batches are fabricated, packaged/labelled, and tested in compliance with them.

Deviation

Any failure to comply with established written procedures, including Standard Operating Procedures (SOPs), protocols, master formulas, working instructions, or cGMP standards; classified as planned or unplanned.

Manufacturing Master Formula (MMF)

A formally authorized document specifying raw material quantities, packaging materials, equipment, in-process controls, and detailed stepwise processing instructions to produce a specified quantity of finished drug product.

Packaging Master Formula (PMF)

A master document covering packaging operations, specifying package sizes, standard packaging materials with specification codes, line clearance procedures, in-process controls, and expected yield limits.

Batch Production Record (BPR)

A uniquely numbered, controlled document that provides step-by-step documentation showing when, how, by whom, with what equipment, and under what conditions a specific production batch was manufactured.

Line Clearance

A documented physical and administrative check ensuring that equipment, transfer lines, and packaging workstations are clean, suitable, and completely free of previous products, residues, and labels before new operations begin.

Annual Product Quality Review (APQR)

A periodic rolling quality review of all drugs conducted at least annually to verify process consistency, assess specification appropriateness, identify adverse trends, and determine necessary corrective actions or revalidations.

Section C.02.012

A GMP regulation requiring fabricators, packagers/labellers, distributors, importers, and wholesalers to maintain a system of control permitting rapid drug recall and to maintain an ongoing self-inspection program.

Drug Recall

An action taken to return, exchange, replace, or remove a drug product from distribution after discovering defects that could hinder product performance, harm consumer health, or violate regulations.

Type 1 Recall

A recall category assigned when there is a reasonable probability that the use of, or exposure to, a recalled product will cause serious adverse health consequences or death.

Type 2 Recall

A recall category assigned when exposure to a recalled product may cause temporary adverse health consequences, or where the probability of serious adverse health consequences is remote.

Type 3 Recall

A recall category assigned when the use of, or exposure to, a recalled product is not likely to cause any adverse health consequences.

Self-Inspection (Internal Audit)

An unbiased, independent review of systems, processes, and operations conducted at least annually according to written procedures to evaluate GMP compliance, identify shortcomings, and recommend corrective actions.

Section C.02.013

A GMP regulation requiring drug establishments to maintain an on-site quality control department in Canada that functions and reports to management independently of manufacturing, processing, packaging, and sales units.

Quality Control (QC)

The part of GMP concerned with sampling, specifications, and testing, as well as organization, documentation, and formal release procedures for materials and finished products.

Section C.02.014

A GMP regulation mandating that no lot of drug, raw material, packaging material, returned product, or reprocessed drug may be used or made available for sale without prior approval by the quality control department head.

Reprocessing

The introduction of an in-process batch or finished lot back into previously defined and validated steps of the authorized manufacturing process, requiring prior quality control department approval.

Reworking

Subjecting an in-process batch or finished product that does not meet specifications to new, non-standard processing steps, requiring prior QC approval based on documented scientific data and validation.

Section C.02.015

A GMP regulation requiring that all methods and procedures affecting drug quality be examined and approved by QC before implementation, complaints be investigated, and required tests be performed by a competent laboratory.